🔗 Share this article

Given that the US undertakes unprecedented revisions to its vaccine recommendations, a particular individual appears in a surprising turn: Høeg, a US-based sports physician and epidemiologist who initially gained attention by casting doubt on coronavirus vaccines throughout the pandemic and has zeroed in on potential fatalities after COVID-19 immunization in her short position at the FDA.

Proposed Shifts to Childhood Vaccine Program

Agency leaders were set to reveal radical changes to the pediatric vaccination calendar earlier this month, aligning the US with Denmark’s national calendar, sources say – a major change that would put the US at odds with much of the world with little proof for public health gain. This reveal has been pushed back until the coming year.

Rather than Vinay Prasad, Høeg is scheduled to speak at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to run the office this calendar year.

Consolidating Power at the FDA

This interim role might represent a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

Høeg has often pushed for ending specific childhood shot schedules in the US to become more similar to Denmark's approach, a nation with universal health coverage and a number of inhabitants about the population of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccination policy – typically the purview of Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Concerns Over Background

Dr. Høeg has no obvious background in medication creation, oversight or leadership, which has been typical for former directors of the biologics center. She has worked at the FDA as a senior adviser to the agency head and CBER since March.

“It seems she lacks to have any of the qualifications” for leading the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in managing a large organization. She lacks background in drug approvals.”

Past commissioners of the center would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the type of experience that former directors who ran the center have had.”

This division has an immense range of responsibilities at the FDA, Woodcock emphasized.

“Everybody just zeroes in on the novel medication approvals, but the generic drug division authorizes a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and so forth, and all of those need to be supervised,” Woodcock explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Furthermore, a substantial leadership element to the job, which oversees in excess of 5,000 personnel. “It’s a enormous administrative position, if you perform it correctly,” the former official said.

Official Statement and Controversial Initiatives

In response to inquiries about Dr. Høeg's credentials and whether this appointment signifies more teamwork among regulatory chiefs on immunizations, a spokesperson responded that the “questions are based on incorrect assumptions”.

“Her experience aligns with the functions of her position,” the official said, pointing to the time Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Høeg inherits the commissioner’s controversial fast-track approval initiative, a contentious expedited therapy clearance system that apparently troubled her predecessors. “How are these therapies being chosen for this expedited pathway? Who makes the calls?” Dr. Howard said. “There’s a lot of lack of transparency occurring at the agency right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards less stringent rules of most medications, except for immunizations.”

Documented Past Work on Immunizations

With immunizations, Høeg has a more established, if concerning, track record, Howard said. She authored a study using non-validated public submissions to estimate the rate of myocarditis after COVID-19 vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to suggest Covid vaccinations are pose a greater threat than they are.

Among her “wish list” for the current government featured revising rules for novel immunizations and discontinuing “non-essential” vaccines, she said following the vote on a online show. At the FDA, Dr. Høeg has according to sources suggested barring adolescent males from getting COVID-19 vaccinations.

“She is an all-around ideologue who commences with her beliefs and reverse-engineers to retrofit the science in a very deceptive, dishonest manner,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined fellow skeptics, {like|